APA (7th ed.) Citation

Lim, B., Porter, C., Woods, M., Suzuki, M., Morita, D., Shaw, A. R., . . . Vasileiou, S. Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Lim, Bora, Caroline Porter, Mae Woods, Masataka Suzuki, Daisuke Morita, Amanda Rosewell Shaw, Greyson Biegert, and Spyridoula Vasileiou. Additional Expression of T-cell Engager in Clinically Tested Oncolytic Adeno-immunotherapy Redirects Tumor-infiltrated, Irrelevant T Cells Against Cancer Cells to Enhance Antitumor Immunity. BMJ Publishing Group.

MLA (9th ed.) Citation

Lim, Bora, et al. Additional Expression of T-cell Engager in Clinically Tested Oncolytic Adeno-immunotherapy Redirects Tumor-infiltrated, Irrelevant T Cells Against Cancer Cells to Enhance Antitumor Immunity. BMJ Publishing Group.